Emily Tai

Emily Tai is an Analyst at Ally Bridge Group in New York, where she supports the firm's private equity strategy with a distinct focus on therapeutics within the healthcare sector. In this role, she conducts due diligence, market research, and financial analysis related to investments in innovative life sciences and medical technology companies.

Before joining Ally Bridge Group in December 2023, Emily held analyst positions at 6 Dimensions Capital, where she focused on healthcare and biotech investments, and interned in institutional banking at DBS Bank. At Ally Bridge Group, her responsibilities include identifying emerging opportunities in biotechnology and therapeutics, underscoring her expertise in these subsectors.

Emily holds a Bachelor of Science degree from Cornell University, equipping her with a strong analytical and research foundation tailored to evaluating healthcare assets. Her experience reflects a clear investment focus on therapeutics, healthcare, and biotech sectors, contributing to the group's mission of investing in high-impact life science innovations.